Several randomised clinical trials have reported an association between the use of tumour necrosis factor inhibitors (TNFi) and drug-induced liver injury.13–16 Additionally, increased production of Interleukin 17A (IL-17A) has been observed in various liver diseases.17,18 Therefore, targeting IL-17 in patients with psoriatic arthritis (PsA) may prevent hepatic complications such as NAFLD.19 In our analysis, among those PsA patients that were on biologics almost 40% were on IL-17A inhibitors. Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.